HEADER HYDROLASE 28-MAY-09 2WJO TITLE HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH TITLE 2 CYCLOHEXANECARBOXYLIC ACID (2-(2-AM INO-6-PHENOXY-4H- TITLE 3 QUINAZOLIN-3-YL)-2-CYCLOHEXYL-ETHYL)-AMIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: BETA-SECRETASE 1; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: RESIDUES 58-460; COMPND 5 SYNONYM: BETA SECRETASE, BETA-SITE AMYLOID PRECURSOR COMPND 6 PROTEIN CLEAVING ENZYME 1, BETA-SITE APP CLEAVING ENZYME COMPND 7 1, MEMBRANE-ASSOCIATED ASPARTIC PROTEASE 2, MEMAPSIN-2, COMPND 8 ASPARTYL PROTEASE 2, ASP 2, ASP2; COMPND 9 EC: 3.4.23.46; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: DROSOPHILA; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FRUIT FLIES; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7215 KEYWDS ZYMOGEN, MEMBRANE, HYDROLASE, GLYCOPROTEIN, TRANSMEMBRANE EXPDTA X-RAY DIFFRACTION AUTHOR M.MATHIEU,A.S.DUPUY REVDAT 3 13-JUL-11 2WJO 1 REMARK REVDAT 2 25-MAY-11 2WJO 1 JRNL REMARK SEQADV DBREF REVDAT 1 02-MAR-10 2WJO 0 JRNL AUTH A.NICHOLLS,G.B.MCGAUGHEY,R.P.SHERIDAN,A.C.GOOD, JRNL AUTH 2 G.WARREN,M.MATHIEU,S.W.MUCHMORE,S.P.BROWN, JRNL AUTH 3 J.A.GRANT,J.A.HAIGH,N.NEVINS,A.N.JAIN,B.KELLEY JRNL TITL MOLECULAR SHAPE AND MEDICINAL CHEMISTRY: A JRNL TITL 2 PERSPECTIVE. JRNL REF J.MED.CHEM. V. 53 3862 2010 JRNL REFN ISSN 0022-2623 JRNL PMID 20158188 JRNL DOI 10.1021/JM900818S REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER/TNT REMARK 3 AUTHORS : BLANC,ROVERSI,VONRHEIN,BRICOGNE,TRONRUD, REMARK 3 : TEN EYCK,MATTHEWS REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 74.95 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.0 REMARK 3 COMPLETENESS FOR RANGE (%) : 97.37 REMARK 3 NUMBER OF REFLECTIONS : 21476 REMARK 3 REMARK 3 USING DATA ABOVE SIGMA CUTOFF. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.1960 REMARK 3 R VALUE (WORKING SET) : 0.1922 REMARK 3 FREE R VALUE : 0.2402 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 7.8 REMARK 3 FREE R VALUE TEST SET COUNT : 1684 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 9 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.65 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 97.37 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 3454 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2388 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 3188 REMARK 3 BIN R VALUE (WORKING SET) : 0.2347 REMARK 3 BIN FREE R VALUE : 0.2892 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 7.70 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 266 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2989 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 35 REMARK 3 SOLVENT ATOMS : 156 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 46.559 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 38.58 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -18.34068135 REMARK 3 B22 (A**2) : -5.96959044 REMARK 3 B33 (A**2) : 24.31027179 REMARK 3 B12 (A**2) : 0.00000000 REMARK 3 B13 (A**2) : 0.00000000 REMARK 3 B23 (A**2) : 0.00000000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.291 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.928 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES RMS WEIGHT COUNT REMARK 3 BOND LENGTHS (A) : 0.006 ; 2.00 ; 3107 REMARK 3 BOND ANGLES (DEGREES) : 0.987 ; 2.00 ; 4207 REMARK 3 TORSION ANGLES (DEGREES) : 21.464 ; 0.00 ; 564 REMARK 3 PSEUDOROTATION ANGLES (DEGREES) : NULL ; NULL ; NULL REMARK 3 TRIGONAL CARBON PLANES (A) : 0.005 ; 2.00 ; 72 REMARK 3 GENERAL PLANES (A) : 0.013 ; 5.00 ; 457 REMARK 3 ISOTROPIC THERMAL FACTORS (A**2) : 1.286 ; 20.00 ; 3107 REMARK 3 NON-BONDED CONTACTS (A) : 0.045 ; 5.00 ; 46 REMARK 3 REMARK 3 INCORRECT CHIRAL-CENTERS (COUNT) : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE REMARK 3 RIDING POSITIONS. REMARK 4 REMARK 4 2WJO COMPLIES WITH FORMAT V. 3.20, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 28-MAY-09. REMARK 100 THE PDBE ID CODE IS EBI-39950. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 30-JAN-07 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID23-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0723 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 21507 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.50 REMARK 200 RESOLUTION RANGE LOW (A) : 74.95 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.0 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.1 REMARK 200 DATA REDUNDANCY : 5.6 REMARK 200 R MERGE (I) : 0.11 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 4.80 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.64 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.0 REMARK 200 DATA REDUNDANCY IN SHELL : 5.7 REMARK 200 R MERGE FOR SHELL (I) : 0.34 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.90 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: IN-HOUSE APOSTRUCTURE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 64.6 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.5 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 11% PEG8000 50MM HEPES PH7.5 REMARK 280 200MM NACL 15% GLYCEROL 10% ACETONITRILE REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 2 2 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -X,Y,-Z+1/2 REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 52.90000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 52.90000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 46.59108 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 63.27350 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 46.59115 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 63.27357 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 52.90000 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 46.59115 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 63.27357 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 52.90000 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 46.59108 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 63.27350 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -3 REMARK 465 SER A -2 REMARK 465 GLY A 158 REMARK 465 PHE A 159 REMARK 465 PRO A 160 REMARK 465 LEU A 161 REMARK 465 ASN A 162 REMARK 465 GLN A 163 REMARK 465 SER A 164 REMARK 465 GLU A 165 REMARK 465 VAL A 166 REMARK 465 THR A 389 REMARK 465 ASP A 390 REMARK 465 GLU A 391 REMARK 465 SER A 392 REMARK 465 THR A 393 REMARK 465 LEU A 394 REMARK 465 MET A 395 REMARK 465 THR A 396 REMARK 465 ILE A 397 REMARK 465 ALA A 398 REMARK 465 TYR A 399 REMARK 465 GLY A 400 REMARK 465 ASP A 401 REMARK 465 LEU A 402 REMARK 465 HIS A 403 REMARK 465 HIS A 404 REMARK 465 HIS A 405 REMARK 465 HIS A 406 REMARK 465 HIS A 407 REMARK 465 HIS A 408 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 388 CA C O CB CG CD OE1 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 ND1 HIS A 181 ND1 HIS A 181 3555 2.14 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 72 -76.88 -34.28 REMARK 500 LYS A 75 168.84 169.86 REMARK 500 HIS A 89 49.97 -109.16 REMARK 500 PHE A 108 -61.96 -95.60 REMARK 500 ASN A 114 0.76 88.33 REMARK 500 ASP A 131 0.26 -69.87 REMARK 500 TRP A 197 -80.29 -152.33 REMARK 500 LYS A 214 88.38 39.44 REMARK 500 TYR A 222 105.37 -50.88 REMARK 500 ASP A 223 -61.77 95.76 REMARK 500 ASP A 311 -164.18 -57.05 REMARK 500 ALA A 313 -67.75 70.19 REMARK 500 GLN A 316 -81.87 -34.57 REMARK 500 HIS A 362 -158.68 -151.91 REMARK 500 REMARK 500 REMARK: NULL REMARK 600 REMARK 600 HETEROGEN REMARK 600 CYCLOHEXANECARBOXYLIC ACID (2-(2-AM REMARK 600 INO-6-PHENOXY-4H-QUINAZOLIN-3-YL)-2 REMARK 600 -CYCLOHEXYL-ETHYL)-AMIDE (QUD): EXAMPLE 20 OF PATENTS REMARK 600 WO06-017844 AND WO06-017836 REMARK 700 REMARK 700 SHEET REMARK 700 THE SHEET STRUCTURE OF THIS MOLECULE IS BIFURCATED. IN REMARK 700 ORDER TO REPRESENT THIS FEATURE IN THE SHEET RECORDS BELOW, REMARK 700 TWO SHEETS ARE DEFINED. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE QUD A1389 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1XN3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO REMARK 900 A LONGINHIBITOR WITH ADDITIONAL UPSTREAM REMARK 900 RESIDUES. REMARK 900 RELATED ID: 2WF3 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 6-(ETHYLAMINO REMARK 900 )-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY REMARK 900 )PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL)PROPYL REMARK 900 )-1-METHYL-1,3,4,5-TETRAHYDRO-2,1- REMARK 900 BENZOTHIAZEPINE-8-CARBOXAMIDE 2,2-DIOXIDE REMARK 900 RELATED ID: 2WF1 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N REMARK 900 -((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY) REMARK 900 PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL)PROPYL)- REMARK 900 1-METHYL-3,4-DIHYDRO-1H-(1,2,5) REMARK 900 THIADIAZEPINO(3,4,5-HI)INDOLE-9- REMARK 900 CARBOXAMIDE 2,2-DIOXIDE REMARK 900 RELATED ID: 2VNM RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 3-(1,1- REMARK 900 DIOXIDOTETRAHYDRO-2H-1,2-THIAZIN-2-YL)-5 REMARK 900 -(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( REMARK 900 PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL) REMARK 900 METHYL)AMINO)PROPYL)BENZAMIDE REMARK 900 RELATED ID: 2WF4 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1- REMARK 900 METHYL-N-((1S)-2-OXO-1-(PHENYLMETHYL)-3-( REMARK 900 TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)-1,3 REMARK 900 ,4,6-TETRAHYDRO(1,2)THIAZEPINO(5,4,3- REMARK 900 CD)INDOLE-8-CARBOXAMIDE 2,2-DIOXIDE REMARK 900 RELATED ID: 2FDP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED REMARK 900 WITH AN AMINO-ETHYLENE INHIBITOR REMARK 900 RELATED ID: 2VJ6 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R REMARK 900 )-3-(((1S)-2-(CYCLOHEXYLAMINO)-1-METHYL-2- REMARK 900 OXOETHYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL) REMARK 900 PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- REMARK 900 PYRROLIDINYL)BENZAMIDE REMARK 900 RELATED ID: 2WF2 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 8-ETHYL-N REMARK 900 -((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY) REMARK 900 PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL)PROPYL)- REMARK 900 1-METHYL-3,4,7,8-TETRAHYDRO-1H,6H-(1, REMARK 900 2,5)THIADIAZEPINO(5,4,3-DE)QUINOXALINE- REMARK 900 10-CARBOXAMIDE 2,2-DIOXIDE REMARK 900 RELATED ID: 1YM4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE REMARK 900 COMPLEXED WITHNVP-AMK640 REMARK 900 RELATED ID: 1SGZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE REMARK 900 CATALYTICDOMAIN. REMARK 900 RELATED ID: 1UJK RELATED DB: PDB REMARK 900 VHS DOMAIN OF HUMAN GGA1 COMPLEXED WITH C REMARK 900 -TERMINALPHOSPHOPEPTIDE FROM BACE REMARK 900 RELATED ID: 2VA7 RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE REMARK 900 COMPLEXED WITH COMPOUND 27 REMARK 900 RELATED ID: 2WEZ RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 1-ETHYL-N REMARK 900 -((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY) REMARK 900 PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL)PROPYL)- REMARK 900 4-(2-OXO-1-PYRROLIDINYL)-1H-INDOLE-6- REMARK 900 CARBOXAMIDE REMARK 900 RELATED ID: 1YM2 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE REMARK 900 COMPLEXED WITHNVP-AUR200 REMARK 900 RELATED ID: 1PY1 RELATED DB: PDB REMARK 900 COMPLEX OF GGA1-VHS DOMAIN AND BETA- REMARK 900 SECRETASE C-TERMINALPHOSPHOPEPTIDE REMARK 900 RELATED ID: 1W50 RELATED DB: PDB REMARK 900 APO STRUCTURE OF BACE (BETA SECRETASE) REMARK 900 RELATED ID: 2VJ7 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO REMARK 900 )-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3 REMARK 900 -(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) REMARK 900 PROPYL)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE REMARK 900 RELATED ID: 2WF0 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N REMARK 900 -((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-((( REMARK 900 3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO)PROPYL REMARK 900 )-8-(2-OXO-1-PYRROLIDINYL)-6- REMARK 900 QUINOLINECARBOXAMIDE REMARK 900 RELATED ID: 1W51 RELATED DB: PDB REMARK 900 BACE (BETA SECRETASE) IN COMPLEX WITH A REMARK 900 NANOMOLAR NON-PEPTIDIC INHIBITOR REMARK 900 RELATED ID: 1TQF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE REMARK 900 COMPLEXED WITH L-124,671 REMARK 900 RELATED ID: 1M4H RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED REMARK 900 WITHINHIBITOR OM00-3 REMARK 900 RELATED ID: 1XN2 RELATED DB: PDB REMARK 900 NEW SUBSTRATE BINDING POCKETS FOR BETA- REMARK 900 SECRETASE. REMARK 900 RELATED ID: 2VIY RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R REMARK 900 )-3-(((1S)-2-(CYCLOHEXYLAMINO)-1-METHYL-2- REMARK 900 OXOETHYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL) REMARK 900 PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE REMARK 900 RELATED ID: 2VA6 RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE REMARK 900 COMPLEXED WITH COMPOUND 24 REMARK 900 RELATED ID: 2VIE RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R REMARK 900 )-1-BENZYL-2-HYDROXY-3-((1,1,5- REMARK 900 TRIMETHYLHEXYL)AMINO)PROPYL)-3-(ETHYLAMINO)-5 REMARK 900 -(2-OXOPYRROLIDIN-1-YL)BENZAMIDE REMARK 900 RELATED ID: 2VIZ RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R REMARK 900 )-3-(((1S)-2-(CYCLOHEXYLAMINO)-1-METHYL-2- REMARK 900 OXOETHYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL) REMARK 900 PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-( REMARK 900 PROPYLOXY)BENZAMIDE REMARK 900 RELATED ID: 2B8L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE REMARK 900 COMPLEXED WITH L-000384950 REMARK 900 RELATED ID: 2VA5 RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE REMARK 900 COMPLEXED WITH COMPOUND 8C REMARK 900 RELATED ID: 2B8V RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE REMARK 900 COMPLEXED WITH L-L000430,469 REMARK 900 RELATED ID: 1FKN RELATED DB: PDB REMARK 900 STRUCTURE OF BETA-SECRETASE COMPLEXED WITH REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1XS7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE- REMARK 900 DERIVED NOVELINHIBITOR BOUND TO HUMAN BRAIN REMARK 900 MEMAPSIN 2 (BETA-SECRETASE). REMARK 900 RELATED ID: 2VIJ RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 3-(1,1- REMARK 900 DIOXIDOTETRAHYDRO-2H-1,2-THIAZIN-2-YL)-5 REMARK 900 -(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( REMARK 900 PHENYLMETHYL)-3-(1,2,3,4-TETRAHYDRO-1- REMARK 900 NAPHTHALENYLAMINO)PROPYL)BENZAMIDE REMARK 900 RELATED ID: 2VKM RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF GRL-8234 BOUND TO REMARK 900 BACE (BETA-SECRETASE) REMARK 900 RELATED ID: 2VJ9 RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R REMARK 900 )-3-(CYCLOHEXYLAMINO)-2-HYDROXY-1-( REMARK 900 PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO REMARK 900 -1-PYRROLIDINYL)BENZAMIDE REMARK 900 RELATED ID: 2VNN RELATED DB: PDB REMARK 900 HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N REMARK 900 -((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-((( REMARK 900 3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO)PROPYL REMARK 900 )-1-METHYL-3,4-DIHYDRO-1H-(1,2,5) REMARK 900 THIADIAZEPINO(3,4,5-HI)INDOLE-9- REMARK 900 CARBOXAMIDE 2,2-DIOXIDE REMARK 900 RELATED ID: 1UJJ RELATED DB: PDB REMARK 900 VHS DOMAIN OF HUMAN GGA1 COMPLEXED WITH C REMARK 900 -TERMINAL PEPTIDEFROM BACE REMARK 999 REMARK 999 SEQUENCE REMARK 999 PRESENCE OF PROPEPTIDE (-3 TO 0) AND CTERMINAL HISTAG (400 TO 408) DBREF 2WJO A -3 399 UNP P56817 BACE1_HUMAN 58 460 SEQADV 2WJO GLY A 400 UNP P56817 EXPRESSION TAG SEQADV 2WJO ASP A 401 UNP P56817 EXPRESSION TAG SEQADV 2WJO LEU A 402 UNP P56817 EXPRESSION TAG SEQADV 2WJO HIS A 403 UNP P56817 EXPRESSION TAG SEQADV 2WJO HIS A 404 UNP P56817 EXPRESSION TAG SEQADV 2WJO HIS A 405 UNP P56817 EXPRESSION TAG SEQADV 2WJO HIS A 406 UNP P56817 EXPRESSION TAG SEQADV 2WJO HIS A 407 UNP P56817 EXPRESSION TAG SEQADV 2WJO HIS A 408 UNP P56817 EXPRESSION TAG SEQRES 1 A 412 GLY SER PHE VAL GLU MET VAL ASP ASN LEU ARG GLY LYS SEQRES 2 A 412 SER GLY GLN GLY TYR TYR VAL GLU MET THR VAL GLY SER SEQRES 3 A 412 PRO PRO GLN THR LEU ASN ILE LEU VAL ASP THR GLY SER SEQRES 4 A 412 SER ASN PHE ALA VAL GLY ALA ALA PRO HIS PRO PHE LEU SEQRES 5 A 412 HIS ARG TYR TYR GLN ARG GLN LEU SER SER THR TYR ARG SEQRES 6 A 412 ASP LEU ARG LYS GLY VAL TYR VAL PRO TYR THR GLN GLY SEQRES 7 A 412 LYS TRP GLU GLY GLU LEU GLY THR ASP LEU VAL SER ILE SEQRES 8 A 412 PRO HIS GLY PRO ASN VAL THR VAL ARG ALA ASN ILE ALA SEQRES 9 A 412 ALA ILE THR GLU SER ASP LYS PHE PHE ILE ASN GLY SER SEQRES 10 A 412 ASN TRP GLU GLY ILE LEU GLY LEU ALA TYR ALA GLU ILE SEQRES 11 A 412 ALA ARG PRO ASP ASP SER LEU GLU PRO PHE PHE ASP SER SEQRES 12 A 412 LEU VAL LYS GLN THR HIS VAL PRO ASN LEU PHE SER LEU SEQRES 13 A 412 GLN LEU CYS GLY ALA GLY PHE PRO LEU ASN GLN SER GLU SEQRES 14 A 412 VAL LEU ALA SER VAL GLY GLY SER MET ILE ILE GLY GLY SEQRES 15 A 412 ILE ASP HIS SER LEU TYR THR GLY SER LEU TRP TYR THR SEQRES 16 A 412 PRO ILE ARG ARG GLU TRP TYR TYR GLU VAL ILE ILE VAL SEQRES 17 A 412 ARG VAL GLU ILE ASN GLY GLN ASP LEU LYS MET ASP CYS SEQRES 18 A 412 LYS GLU TYR ASN TYR ASP LYS SER ILE VAL ASP SER GLY SEQRES 19 A 412 THR THR ASN LEU ARG LEU PRO LYS LYS VAL PHE GLU ALA SEQRES 20 A 412 ALA VAL LYS SER ILE LYS ALA ALA SER SER THR GLU LYS SEQRES 21 A 412 PHE PRO ASP GLY PHE TRP LEU GLY GLU GLN LEU VAL CYS SEQRES 22 A 412 TRP GLN ALA GLY THR THR PRO TRP ASN ILE PHE PRO VAL SEQRES 23 A 412 ILE SER LEU TYR LEU MET GLY GLU VAL THR ASN GLN SER SEQRES 24 A 412 PHE ARG ILE THR ILE LEU PRO GLN GLN TYR LEU ARG PRO SEQRES 25 A 412 VAL GLU ASP VAL ALA THR SER GLN ASP ASP CYS TYR LYS SEQRES 26 A 412 PHE ALA ILE SER GLN SER SER THR GLY THR VAL MET GLY SEQRES 27 A 412 ALA VAL ILE MET GLU GLY PHE TYR VAL VAL PHE ASP ARG SEQRES 28 A 412 ALA ARG LYS ARG ILE GLY PHE ALA VAL SER ALA CYS HIS SEQRES 29 A 412 VAL HIS ASP GLU PHE ARG THR ALA ALA VAL GLU GLY PRO SEQRES 30 A 412 PHE VAL THR LEU ASP MET GLU ASP CYS GLY TYR ASN ILE SEQRES 31 A 412 PRO GLN THR ASP GLU SER THR LEU MET THR ILE ALA TYR SEQRES 32 A 412 GLY ASP LEU HIS HIS HIS HIS HIS HIS HET QUD A1389 35 HETNAM QUD 2-AMINO-3-{(1R)-1-CYCLOHEXYL-2- HETNAM 2 QUD [(CYCLOHEXYLCARBONYL)AMINO]ETHYL}-6-PHENOXYQUINAZOLIN-3- HETNAM 3 QUD IUM FORMUL 2 QUD C29 H37 N4 O2 1+ FORMUL 3 HOH *156(H2 O) HELIX 1 1 GLN A 53 SER A 57 5 5 HELIX 2 2 TYR A 123 ALA A 127 5 5 HELIX 3 3 PRO A 135 THR A 144 1 10 HELIX 4 4 ASP A 180 SER A 182 5 3 HELIX 5 5 ASP A 216 TYR A 222 5 7 HELIX 6 6 LYS A 238 SER A 253 1 16 HELIX 7 7 PRO A 258 LEU A 263 1 6 HELIX 8 8 PRO A 276 PHE A 280 5 5 HELIX 9 9 LEU A 301 TYR A 305 1 5 HELIX 10 10 GLY A 334 GLU A 339 1 6 HELIX 11 11 ARG A 347 ARG A 349 5 3 HELIX 12 12 ASP A 378 GLY A 383 5 6 SHEET 1 AA 3 ARG A 61 PRO A 70 0 SHEET 2 AA 3 LYS A 75 SER A 86 -1 O TRP A 76 N VAL A 69 SHEET 3 AA 3 GLY A 13 VAL A 20 -1 O THR A 19 N SER A 86 SHEET 1 AB 7 ARG A 61 PRO A 70 0 SHEET 2 AB 7 LYS A 75 SER A 86 -1 O TRP A 76 N VAL A 69 SHEET 3 AB 7 VAL A 95 ASP A 106 -1 O VAL A 95 N VAL A 85 SHEET 4 AB 7 PHE A 38 GLY A 41 1 O PHE A 38 N ALA A 100 SHEET 5 AB 7 GLY A 117 GLY A 120 -1 O ILE A 118 N ALA A 39 SHEET 6 AB 7 GLN A 25 ASP A 32 1 O LEU A 30 N LEU A 119 SHEET 7 AB 7 GLY A 13 VAL A 20 -1 O TYR A 14 N VAL A 31 SHEET 1 AC 5 GLN A 211 ASP A 212 0 SHEET 2 AC 5 ILE A 203 ILE A 208 -1 O ILE A 208 N GLN A 211 SHEET 3 AC 5 ILE A 283 MET A 288 -1 O SER A 284 N GLU A 207 SHEET 4 AC 5 GLN A 294 ILE A 300 -1 O PHE A 296 N LEU A 287 SHEET 5 AC 5 ALA A 369 VAL A 375 -1 O ALA A 369 N THR A 299 SHEET 1 AD 4 SER A 225 VAL A 227 0 SHEET 2 AD 4 THR A 331 MET A 333 1 O THR A 331 N ILE A 226 SHEET 3 AD 4 LEU A 234 PRO A 237 -1 O ARG A 235 N VAL A 332 SHEET 4 AD 4 ILE A 324 SER A 327 1 O SER A 325 N LEU A 236 SHEET 1 AE 3 VAL A 268 TRP A 270 0 SHEET 2 AE 3 ASP A 318 PHE A 322 -1 O ASP A 318 N TRP A 270 SHEET 3 AE 3 LEU A 306 VAL A 309 -1 O ARG A 307 N LYS A 321 SSBOND 1 CYS A 155 CYS A 359 1555 1555 2.04 SSBOND 2 CYS A 217 CYS A 382 1555 1555 2.03 SSBOND 3 CYS A 269 CYS A 319 1555 1555 2.03 CISPEP 1 SER A 22 PRO A 23 0 0.52 CISPEP 2 ARG A 128 PRO A 129 0 4.52 CISPEP 3 GLY A 372 PRO A 373 0 -2.22 SITE 1 AC1 12 LEU A 30 ASP A 32 GLY A 34 VAL A 69 SITE 2 AC1 12 TYR A 71 GLY A 74 LYS A 75 TYR A 198 SITE 3 AC1 12 ASP A 228 GLY A 230 THR A 231 ARG A 235 CRYST1 93.182 126.547 105.800 90.00 90.00 90.00 C 2 2 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010732 0.000000 0.000000 0.00000 SCALE2 0.000000 0.007902 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009452 0.00000 MASTER 475 0 1 12 22 0 3 6 0 0 0 32 END